30-Jun-11 | 30-Jun-10 | 30-Jun-09 | 30-Jun-08 | |||||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Asia | 0.13 | 2% | 0.02 | n/a | 0.01 | n/a | n/a | n/a |
Europe | 1.45 | 25% | 0.78 | 14% | 0.76 | 19% | 0.63 | 31% |
UK | 0.27 | 5% | 0.41 | 7% | 0.69 | 17% | 0.55 | 27% |
USA | 3.90 | 68% | 4.53 | 79% | 2.51 | 63% | 0.88 | 43% |
Total | 5.75 | 100% | 5.74 | 100% | 3.97 | 100% | 2.07 | 100% |
Profit Before Tax | ||||||||
Unanalysed | 0.36 | 100% | 0.35 | 100% | (0.67) | 100% | (1.33) | 100% |
Total | 0.36 | 100% | 0.35 | 100% | (0.67) | 100% | (1.33) | 100% |
30-Jun-11 | 30-Jun-10 | 30-Jun-09 | 30-Jun-08 | |||||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Bio-markers | n/a | n/a | n/a | n/a | 0.67 | 17% | 0.15 | 7% |
Contract Research Services | 3.00 | 52% | 2.52 | 44% | 2.30 | 58% | 1.91 | 93% |
Novel Therapies | 1.62 | 28% | 2.42 | 42% | 1.00 | 25% | n/a | n/a |
Personalised Medicine | 1.13 | 20% | 0.80 | 14% | n/a | n/a | n/a | n/a |
Total | 5.75 | 100% | 5.74 | 100% | 3.97 | 100% | 2.07 | 100% |
Profit Before Tax | ||||||||
Bio-markers | n/a | n/a | n/a | n/a | 0.01 | n/a | (0.06) | n/a |
Contract Research Services | 0.97 | 57% | 0.72 | n/a | 0.56 | n/a | 0.46 | n/a |
Novel Therapies | 0.64 | 38% | 0.99 | n/a | (0.16) | n/a | (0.91) | n/a |
Personalised Medicine | 0.09 | 5% | (0.10) | n/a | n/a | n/a | n/a | n/a |
Unanalysed | (1.34) | n/a | (1.26) | n/a | (1.08) | n/a | (0.82) | n/a |
Total | 0.36 | 100% | 0.35 | n/a | (0.67) | n/a | (1.33) | n/a |
You are here: research